2024-04-05 07:12 | CC:ONC | Oncolytics Biotech Inc (2) | 1.56 | In the News525 | Globe says Oncolytics Biotech kept at "outperformer" |
2024-03-12 16:33 | CC:ONC | Oncolytics Biotech Inc (2) | 1.43 | SEDAR Annual Report803 | SEDAR Annual Report |
2024-03-07 19:18 | CC:ONC | Oncolytics Biotech Inc (2) | 1.41 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
2024-03-07 19:18 | CC:ONC | Oncolytics Biotech Inc (2) | 1.41 | SEDAR MD & A815 | SEDAR MD & A |
2024-03-07 16:22 | CC:ONC | Oncolytics Biotech Inc (2) | 1.41 | News Release200 | Oncolytics spends $17.7-million on R&D in 2023 |
2024-03-05 10:34 | CC:ONC | Oncolytics Biotech Inc (2) | 1.37 | News Release200 | Oncolytics files amendment to Goblet phase 1/2 study |
2024-03-04 10:48 | CC:ONC | Oncolytics Biotech Inc (2) | 1.51 | News Release200 | Oncolytics Biotech to release 2023 results March 7 |
2024-02-14 11:37 | CC:ONC | Oncolytics Biotech Inc (2) | 1.41 | News Release200 | Oncolytics expands Goblet anal cancer study enrolment |
2024-01-09 10:31 | CC:ONC | Oncolytics Biotech Inc (2) | 1.81 | News Release200 | Oncolytics Biotech appoints Andrews as director |
2024-01-04 09:40 | CC:ONC | Oncolytics Biotech Inc (2) | 1.76 | News Release200 | Oncolytics Biotech recaps 2023 operations |
2023-12-07 10:16 | CC:ONC | Oncolytics Biotech Inc (2) | 1.91 | News Release200 | Oncolytics presents AWARE-1 data at cancer symposium |
2023-11-09 10:43 | CC:ONC | Oncolytics Biotech Inc (2) | 1.82 | News Release200 | Oncolytics presents Goblet results at IMACC in Rome |
2023-11-09 10:03 | CC:ONC | Oncolytics Biotech Inc (2) | 2.15 | News Release200 | Oncolytics plans to start phase 3 PDAC study mid-2024 |
2023-11-03 13:38 | CC:ONC | Oncolytics Biotech Inc (2) | 2.35 | News Release200 | Oncolytics Biotech presents Aware-1 study data |
2023-11-03 11:33 | CC:ONC | Oncolytics Biotech Inc (2) | 2.43 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
2023-11-03 11:31 | CC:ONC | Oncolytics Biotech Inc (2) | 2.43 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2023-11-03 11:23 | CC:ONC | Oncolytics Biotech Inc (2) | 2.35 | News Release200 | Oncolytics Biotech's Sept. 30 cash at $40-million |
2023-10-23 11:04 | CC:ONC | Oncolytics Biotech Inc (2) | 2.30 | News Release200 | Oncolytics talks Goblet pancreatic cancer study data |
2023-10-23 10:18 | CC:ONC | Oncolytics Biotech Inc (2) | 2.14 | News Release200 | Oncolytics' Goblet study meets efficacy criteria |
2023-10-20 08:06 | CC:ONC | Oncolytics Biotech Inc (2) | 2.22 | News Release200 | Oncolytics Biotech to release Q3 2023 results Nov. 3 |
2023-09-26 10:06 | CC:ONC | Oncolytics Biotech Inc (2) | 3.00 | News Release200 | Oncolytics Biotech receives $5-million research grant |
2023-08-14 12:28 | CC:ONC | Oncolytics Biotech Inc (2) | 2.76 | News Release200 | Oncolytics Biotech spends $3.7M on R&D in Q2 2023 |
2023-08-14 10:17 | CC:ONC | Oncolytics Biotech Inc (2) | 2.73 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2023-08-04 07:57 | CC:ONC | Oncolytics Biotech Inc (2) | 3.01 | News Release200 | Oncolytics Biotech to hold Q2 2023 results call Aug. 14 |
2023-08-03 21:51 | CC:ONC | Oncolytics Biotech Inc (2) | 3.01 | Prospectus Approved3 | Oncolytics Biotech to list additional shares Aug. 8 |
2023-06-22 09:09 | CC:ONC | Oncolytics Biotech Inc (2) | 2.81 | News Release200 | Oncolytics' pelareorep selected for Precision trial |
2023-06-05 09:52 | CC:ONC | Oncolytics Biotech Inc (2) | 2.28 | News Release200 | Oncolytics talks Bracelet-1 phase 2 trial results |
2023-05-10 12:35 | CC:ONC | Oncolytics Biotech Inc (2) | 2.19 | News Release200 | Oncolytics shareholders approve all matters at AGM |
2023-05-05 10:30 | CC:ONC | Oncolytics Biotech Inc (2) | 1.98 | SEDAR MD & A815 | SEDAR MD & A |
2023-05-05 10:28 | CC:ONC | Oncolytics Biotech Inc (2) | 1.98 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2023-05-05 10:02 | CC:ONC | Oncolytics Biotech Inc (2) | 2.14 | News Release200 | Oncolytics Biotech spends $3.5-million on R&D in Q1 |